Non-vitamin K oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban and edoxaban have replaced warfarin as the preferred treatment for reducing stroke risk in patients with atrial fibrillation, according to updated guidelines issued Jan. 28.